New York State Biodefense Commercialization Fund awarded Rover Diagnostics $1.8 million to develop an Affordable and Adaptable real-time Nucleic Acid Amplification Test (NAAT) platform for Rapid Diagnostic Development, Response, and Surveillance.

Since 2019, Rover has been developing the LightSpeed, a sample to answer molecular diagnostic testing solution for use in decentralized settings. The LightSpeed integrates lab based methodologies with multiplex capabilities for future test menu expansion capabilities. The unique technology provides rapid sample processing in